Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
Recognized from query: Pfizer Phase 3 trials. Matching terms were moved into the structured fields above when recognized.
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 710 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "Pfizer Phase 3 trials" Clear all
Not yet recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

NCT07783425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

NCT01564784
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
96
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

NCT00868296
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Day to 12 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
45
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

NCT00814307
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

NCT06890416
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

NCT00754221
View directory record Official record
Conditions
Fibromyalgia
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
View directory record Official record
Conditions
Atrophic Vaginitis, Atrophy, Vaginitis
Interventions
PVC (daily for 21 days, 7 days off), PVC (twice weekly)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
480 participants
Timeline
2005 – 2007
U.S. locations
32
States / cities
Tucson, Arizona • Encinitas, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
97
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2006 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

NCT00811018
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sitaxsentan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

NCT06698796
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Dazukibart
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Glendale, Arizona • Frisco, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

NCT01035346
View directory record Official record
Conditions
Infection
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Cypress, California • Westlake Village, California • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Smoking Cessation & Opioid Dependence Treatment Integration

NCT02854800
View directory record Official record
Conditions
Smoking Cessation, Opioid Related Disorders
Interventions
varenicline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

NCT00413699
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 15, 2026, 10:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

NCT04040192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 15, 2026, 10:45 AM EDT